Why LDH is Elevated in Multiple Myeloma
Elevated lactate dehydrogenase (LDH) in multiple myeloma reflects high tumor burden, aggressive disease biology, and serves as a critical independent prognostic marker for poor outcomes—it indicates increased plasma cell proliferation, extramedullary disease, and resistance to therapy.
Pathophysiologic Mechanisms
LDH elevation in multiple myeloma occurs through several interconnected mechanisms:
Direct Tumor Production
Myeloma cells themselves produce and release substantial amounts of LDH into the circulation 1. This has been directly demonstrated through:
- Immunocytochemical staining showing abundant cytoplasmic LDH in myeloma cells
- Detection of high LDH concentrations in myeloma cell culture supernatants
- Elevated LDH mRNA expression in myeloma cell lines compared to other hematologic malignancies
Markers of Aggressive Disease Biology
High LDH specifically correlates with the most aggressive myeloma subtypes 2:
- Plasma cell leukemia or lymphoma-like features (present in 43% of patients with elevated LDH)
- Plasmablastic morphology rather than mature plasma cell types
- Hypodiploidy (17% of high-LDH patients)
- Extramedullary plasmacytomas that develop during disease progression 3
The LDH isoenzyme pattern shifts toward a "tumor pattern" (increased LDH-3, decreased LDH-1 and LDH-2) in aggressive disease, distinguishing it from the normal pattern seen in patients with controlled myeloma 4, 5.
Clinical and Prognostic Significance
Integration into Risk Stratification
LDH is formally incorporated into multiple myeloma staging systems 6:
Revised International Staging System (R-ISS) defines three risk groups 6:
- R-ISS Stage I: ISS Stage I + standard-risk cytogenetics + normal LDH
- R-ISS Stage II: Intermediate features
- R-ISS Stage III: ISS Stage III + (high-risk cytogenetics OR elevated LDH)
This classification demonstrates that elevated LDH alone is sufficient to classify a patient as high-risk, even without other adverse features.
Independent Prognostic Impact
LDH functions as an independent predictor of outcomes across multiple dimensions 7, 8:
- Treatment resistance: Only 20% of patients with elevated LDH respond to chemotherapy versus 57% with normal LDH 2
- Survival: Median survival of just 9 months with high LDH versus significantly longer with normal levels 2
- Highest relative risk: LDH shows a relative risk of 2.63 (95% CI: 1.75-3.95) for mortality 2
- Relapse prognosis: Elevated LDH at relapse predicts particularly poor outcomes 8
Tumor Burden Correlation
LDH levels increase proportionally with disease burden 6, 9, 10:
- Present in 26% of patients with high tumor mass
- Rises dramatically (up to 27-fold above normal) as disease progresses 3
- Suggests presence of occult extraosseous disease 2
Clinical Implications and Monitoring
Diagnostic Workup
LDH should be measured at diagnosis in all patients as part of standard initial assessment 6, 9, 10. The guidelines consistently recommend:
- Baseline serum LDH measurement
- Integration with β2-microglobulin and albumin for ISS staging
- Combination with FISH cytogenetics for comprehensive risk assessment
Disease Monitoring
Serial LDH measurements provide valuable information about disease trajectory 3, 11:
- Normal LDH at diagnosis that subsequently rises signals disease progression
- Dramatically elevated LDH (>7,500 U/L) indicates fulminant disease requiring urgent intervention
- Should prompt evaluation for extramedullary plasmacytomas before clinical symptoms develop
Treatment Implications
Patients with elevated LDH warrant 7, 12:
- Early intensive treatment rather than standard approaches
- Consideration for clinical trials of novel agents
- More frequent monitoring for disease progression
- Evaluation for extramedullary disease
Common Pitfalls
Do not dismiss mildly elevated LDH: Even modest elevations carry prognostic significance and should trigger enhanced monitoring 11, 13.
Recognize that normal LDH does not exclude myeloma: Approximately 80% of myeloma patients have normal LDH levels, particularly those with more mature plasma cell morphology 5.
Re-evaluate LDH at relapse: Risk status changes over time, and LDH should be reassessed at disease progression as it independently predicts outcomes in the relapsed setting 8.
Consider LDH in resource-limited settings: When expensive cytogenetic testing is unavailable, LDH combined with basic parameters (renal function, ISS stage) provides accessible prognostic information 11.